8 completed. 8 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 7 | Completed 7 |
Follow Influenza Immunization: new trials by email Literature Review of Influenza Immunization trials Research Report on Influenza Immunization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older Pandemic flu H5 mRNA vaccine, Placebo - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 276 | 2024-12-09 | 2026-04-23 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1) - COVID-19 Immunization, Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi | 980 | 2024-11-19 | 2026-05-05 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1) - COVID-19 Immunization, Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi | 980 | 2024-11-18 | 2026-05-05 |
| A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429 - Influenza Immunization, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 908 | 2024-04-01 | 2026-08-04 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 682 | 2022-12-12 | 2025-03-19 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 682 | 2022-11-28 | 2025-03-18 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 560 | 2022-10-03 | 2025-01-24 |
| Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified) - Influenza Immunization, Healthy Volunteers | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 306 | 2021-07-16 | 2025-09-12 |
Influenza, Human (8)
Infections (8) · Orthomyxoviridae Infections (8) · RNA Virus Infections (8) · Respiratory Tract Diseases (8) · Respiratory Tract Infections (8) · Virus Diseases (8)
Influenza Vaccines (4) · Vaccines (3) · 2019-nCoV Vaccine mRNA-1273 (1) · CVnCoV COVID-19 vaccine (1)
Sanofi Pasteur, a Sanofi Company (6) · Sanofi (2)
United States (8) · Puerto Rico (4) · Australia (1) · Honduras (1)